RxDoctor Payments Data

Patrick Kenney, DO

Infectious Disease · Oakland Park, FLNPI 1104129634

Payments from drug & device makers

$8,014in general payments, 2019–2025

Across 27 payments — averaging $296.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$8K
  • Davol Inc.$144
  • AbbVie$71
  • Viiv Healthcare Company$57
  • Insmed, Inc.$30
  • Regeneron Healthcare Solutions, Inc.$11

What the payments were for

  • Speaking & faculty fees$5,38067%
  • Travel & lodging$1,53419%
  • Food & beverage$1,10014%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,014 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$115,362
Medicare patients
294
Services billed
2,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala280$1,167,609
DescovyEmtricitabine/Tenofov Alafenam496$1,037,041
TivicayDolutegravir Sodium98$306,350
TriumeqAbacavir/Dolutegravir/Lamivudi58$240,742
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf39$186,965
CabenuvaCabotegravir/Rilpivirine27$173,718
GenvoyaElviteg/Cob/Emtri/Tenof Alafen39$169,336
JulucaDolutegravir/Rilpivirine36$161,083
PrezcobixDarunavir/Cobicistat57$154,013
DovatoDolutegravir Sodium/Lamivudine37$115,192
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$94,670
PifeltroDoravirine42$76,804
ErtapenemErtapenem Sodium35$19,408
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df21$16,745
Efavirenz-Lamivu-Tenofov DisopEfavirenz/Lamivu/Tenofov Disop12$16,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$7,701$2,373,987815 claims
Viiv Healthcare CompanyTivicay, Triumeq, Cabenuva, Juluca, Dovato$57$997,085256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Oakland Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →